Physician profile
Gregory B Fox
NPI 1427230713
$14,301.73
in general payments reported to CMS, 2019-2025
24 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $715 · 2021: $1,292 · 2022: $2,314 · 2023: $2,900 · 2024: $3,117 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,377 · Education: $402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,376.58 |
| Education | $402.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,376.64 | 2020-2025 | Caplyta |
| Abbvie INC. | $2,341.98 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,617.32 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,008.77 | 2019-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $934.09 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $901.20 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $863.36 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $607.11 | 2021-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $537.07 | 2019-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $463.82 | 2019-2022 | |
| Indivior INC. | $425.11 | 2022-2024 | Perseris |
| Neurocrine Biosciences, INC. | $408.61 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $392.54 | 2023-2025 | Auvelity |
| Allergan, INC. | $361.46 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.53 | 2019-2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $143.36 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $124.99 | 2019 | |
| Almatica Pharma LLC | $124.80 | 2022-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $92.08 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $72.96 | 2021-2022 | |
| Horizon Therapeutics Plc | $65.46 | 2019-2023 | Krystexxa |
| Corium, LLC | $60.39 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Orexo US, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.